Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study
Disc Medicine reports positive Phase 3 results for bitopertin in EPP, meeting all primary and secondary endpoints. NDA resubmission planned.
Share
Why It Matters
Disc Medicine's new medicine worked really well in patient tests. This is a good sign that the company is moving toward selling it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.